Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to assess the interaction of acohol and oral treprostinil.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine

NCT01153386

Pulmonary Arterial Hypertension

COMPLETED PHASE1

Effect of Food on the Pharmacokinetics of Oral Treprostinil

NCT00963001

Hypertension, Pulmonary Pulmonary Arterial Hypertension

COMPLETED PHASE1

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

NCT01172496

Pulmonary Arterial Hypertension

COMPLETED PHASE1

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

NCT01131845

Pulmonary Arterial Hypertension Renal Dysfunction

COMPLETED PHASE1

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

NCT01165476

Pulmonary Arterial Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will compare the effects of ethanol on the PKs of a 1 mg dose of UT-15C in healthy volunteers to determine the in vivo effects of ethanol, including the timing of ethanol consumption in relation to UT-15C ingestion.

This is an open-label, randomized, single-center, four-way (period), crossover study in which 28 healthy volunteers will receive a single 1 mg oral dose of UT-15C and/or ethanol. Eligible subjects will be randomly assigned to one of four treatment sequences such that all subjects will receive all four sequences in a pre-specified order.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Comparison 1

UT-15C 1 mg alone

Group Type ACTIVE_COMPARATOR

UT-15C

Intervention Type DRUG

sustained release oral treprostinil

Comparison 2

UT-15C 1 mg plus ethanol (simultaneously)

Group Type ACTIVE_COMPARATOR

UT-15C

Intervention Type DRUG

sustained release oral treprostinil

ethanol

Intervention Type OTHER

Absolut 100 vodka

Comparison 3

UT-15C 1 mg administered 1 hour before ethanol

Group Type ACTIVE_COMPARATOR

UT-15C

Intervention Type DRUG

sustained release oral treprostinil

ethanol

Intervention Type OTHER

Absolut 100 vodka

Comparison 4

UT-15C 1 mg administered 1 hour after ethanol

Group Type ACTIVE_COMPARATOR

UT-15C

Intervention Type DRUG

sustained release oral treprostinil

ethanol

Intervention Type OTHER

Absolut 100 vodka

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UT-15C

sustained release oral treprostinil

Intervention Type DRUG

ethanol

Absolut 100 vodka

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oral treprostinil alcohol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject voluntarily gives informed consent to participate in the study.
2. Women of child bearing potential includes any female who has experienced menarche and who has not undergone successful surgical sterilization. Women of childbearing potential must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use two different forms of highly effective contraception for the duration of the study, and for at least 30 days after discontinuing study medication. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods used with a spermicide, (3) an intrauterine device, or (4) partner vasectomy. For women of childbearing potential, a negative urine pregnancy test is required at Screening and Baseline prior to initiating study medication.
3. The subject, if male, must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.
4. Healthy male and female subjects aged 21-55 years of age at the time of signing the informed consent.
5. Weight between 55 and 100 kg, with a BMI between 19.0-29.9 kg/m2, inclusive for female subjects and weight between 55 and 120 kg, with a BMI between 19.0-32.0 kg/m2, inclusive for male subjects.
6. Regular consumption of ethanol with no recent changes in pattern of consumption
7. In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion Criteria

1. The subject is pregnant or lactating.
2. Subject has any clinically relevant abnormality identified during the screening physical examination, 12-lead ECG, or laboratory examinations.
3. Subject has a history of anaphylaxis, a previous documented hypersensitivity reaction, or a clinically significant idiosyncratic reaction to any drug.
4. Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
5. Subject has a history of postural hypotension, or unexplained syncope.
6. Subject has a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
7. Subject has a pulse rate that is greater than 90 bpm after sitting at rest for 5 minutes at Screening or Baseline.
8. Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg diastolic at Screening or Baseline.
9. Subject has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.
10. Subject has tested positive at the screening visit for HIV infection, HBsAg, or the HCV antibody.
11. Subject currently uses tobacco products or has a history of tobacco use within two months prior to Baseline.
12. Subject has a history of ethanol abuse or a history of or current impairment of organ function reasonably related to ethanol abuse.
13. Subject has a history of or current evidence of abuse of licit or illicit drugs, including a positive urine screen for drugs of abuse at Screening or Baseline.
14. Subject has a history of abnormal bleeding tendencies.
15. Subject has donated blood or plasma or has lost a significant volume of blood within four weeks prior to Baseline.
16. Subject has clinically significant abnormal laboratory values in the opinion of the treating Investigator.
17. Subject has participated in a research study within the last 30 days.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes